Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00178269 · ClinicalTrials.gov registry record · Phase 2
Low-Dose Taxotere® (Docetaxel) With Concurrent Radiotherapy For Localized, Inoperable Carcinoma Of The Uterine Cervix
A Phase 2 study of Cervix Neoplasm, sponsored by University of Rochester.
- Completed
- Registry status
- Phase 2
- Development phase
- 1
- Study location
NCT00178269 is a Phase 2 study of Cervix Neoplasm that has completed, run by University of Rochester. The trial reports 1 study location across 1 state.
The verdict
NCT00178269, a Phase 2 study of Cervix Neoplasm, has completed, sponsored by University of Rochester.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 1
- Study location
Study Summary
The purpose of this study is to find out how effectively cervix cancer is controlled when radiation is combined with low-dose chemotherapy (Taxotere) . The use of low-dose Taxotere, once per week, with radiation is a new treatment for cervical cancer. This study will also see how well this treatment regimen can be tolerated.
Conditions Studied
Interventions
- DRUG docetaxel
- PROCEDURE Radiation Therapy
Study Locations (1)
New York
- University of Rochester, Dept. Radiation Oncology - Rochester
Trial Details
| Field | Value |
|---|---|
| Start Date | 2005-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00178269
The ClinicalTrials.gov registry entry for NCT00178269 describes a study currently listed as completed, categorized as Phase 2. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is University of Rochester, which has 636 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Cervix Neoplasm appearing as the primary indexed condition, and to 2 interventions - of which docetaxel is the first listed.
NCT00178269 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT00178269 about?
NCT00178269 is a clinical study titled "Low-Dose Taxotere® (Docetaxel) With Concurrent Radiotherapy For Localized, Inoperable Carcinoma Of The Uterine Cervix". The purpose of this study is to find out how effectively cervix cancer is controlled when radiation is combined with low-dose chemotherapy (Taxotere) . The use of low-dose Taxotere, once per week, with radiation is a new treatment for cervical cancer. This study will also see how well this treatment...
What is the current status of trial NCT00178269?
This trial is currently completed. It is a Phase 2 study. The study started on 2005-01.
What conditions does trial NCT00178269 study?
This clinical trial studies the following conditions: Cervix Neoplasm.
What interventions are being tested in trial NCT00178269?
The interventions under investigation include: docetaxel (DRUG), Radiation Therapy (PROCEDURE).
Who is sponsoring clinical trial NCT00178269?
This trial is sponsored by University of Rochester, which has 636 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00178269 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.